LLNI Funded Publications
The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.
Other Authors: McPherson S, Mills K, McMullin MF,
Journal:Journal of translational medicine
Date: December 2018